Posterior Reversible Encephalopathy Syndrome: Diagnosis and Management

Posterior Reversible Encephalopathy Syndrome: Diagnosis and Management

Recognize the parieto-occipital vasogenic edema syndrome triggered by hypertension, eclampsia, and immunosuppressants – and manage it with rapid BP control, seizure protection, and trigger removal.

Clinical Guideline · Neurology · gomdori, MD

Executive Summary

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiologic disorder characterized by bilateral vasogenic edema predominantly affecting the parieto-occipital lobes, presenting with headache, seizures, visual disturbances, encephalopathy, and acute hypertension. Triggers include hypertensive crisis, eclampsia/preeclampsia, calcineurin inhibitors (tacrolimus, cyclosporine), cytotoxic chemotherapy, autoimmune disease, sepsis, and renal failure. Pathophysiology involves either failure of cerebral autoregulation (BP exceeds upper limit, hyperperfusion, blood-brain barrier breakdown) or endothelial dysfunction (drug-induced or cytokine-mediated). MRI shows bilateral T2/FLAIR hyperintensities without diffusion restriction. Management requires (1) controlled BP reduction (MAP 105-125 mmHg) with IV nicardipine, labetalol, or clevidipine; (2) seizure control with levetiracetam or fosphenytoin; (3) magnesium sulfate for eclampsia; (4) immediate withdrawal or substitution of offending immunosuppressants/chemotherapy. Most patients (75-90%) recover completely within 1-3 months, but mortality reaches 3-15% with hemorrhage, status epilepticus, or delayed recognition.

95%
Parieto-occipital edema
75-90%
Complete recovery
15%
Hemorrhagic PRES
3-15%
Mortality

S1. Pathophysiology & Triggers

PRES results from disruption of the blood-brain barrier in regions with sparse sympathetic innervation. The posterior circulation (vertebrobasilar territory) lacks the dense adrenergic protection of the anterior circulation, leaving the parieto-occipital cortex preferentially vulnerable to acute hyperperfusion and endothelial injury. Two complementary mechanisms drive the syndrome.

Mechanism 1: Cerebral Autoregulation Failure

Healthy cerebrovascular autoregulation maintains constant cerebral blood flow across MAP 60-150 mmHg via arteriolar vasoconstriction. When systemic BP exceeds this upper limit (often abrupt rises rather than absolute values), autoregulation breaks down, causing forced vasodilation, hyperperfusion, and hydrostatic transudation of plasma into the interstitium. This explains classic hypertensive PRES from malignant hypertension, pheochromocytoma, renal artery stenosis, and acute glomerulonephritis.

Mechanism 2: Endothelial Dysfunction

Up to 30% of PRES occurs at normal or only mildly elevated BP, implicating direct endothelial injury. Calcineurin inhibitors (tacrolimus, cyclosporine) disrupt endothelial nitric oxide synthase. Cytotoxic chemotherapy (cisplatin, gemcitabine, cytarabine) damages capillary endothelium. Cytokine storm in sepsis, eclampsia, or autoimmune flares releases TNF-alpha, IL-6, and VEGF, all of which increase vascular permeability. The downstream result is identical: vasogenic edema, predominantly posterior.

Common Triggers

CategorySpecific TriggersMechanism
Hypertensive emergenciesMalignant HTN, pheochromocytoma, renal artery stenosis, acute glomerulonephritisAutoregulation breakdown
Pregnancy-relatedEclampsia, preeclampsia, HELLP syndrome, postpartum angiopathyMixed (BP + endothelial)
ImmunosuppressantsTacrolimus, cyclosporine, sirolimus (rare)Endothelial dysfunction
Cytotoxic chemotherapyCisplatin, gemcitabine, cytarabine, methotrexateCapillary endothelial injury
Targeted therapyBevacizumab, sunitinib, sorafenib, CAR-T cell therapyVEGF inhibition / cytokine release
Autoimmune diseaseSLE, scleroderma, GPA, TTP, HUSCytokine-mediated endothelitis
SepsisBacterial sepsis, septic shockCytokine storm + hemodynamic instability
Renal failureAcute kidney injury, dialysis disequilibriumUremia + volume/BP swings
OtherIVIG, blood transfusion, EPO, sympathomimetic abuseVarious
PRES pathophysiology cascade Two converging pathways – autoregulation breakdown and endothelial dysfunction – leading to vasogenic edema PATHWAY 1: BP Surge Malignant HTN, eclampsia, pheo PATHWAY 2: Endothelial Toxin Tacrolimus, chemo, sepsis, VEGF-i MAP exceeds upper autoregulation Forced arteriolar vasodilation eNOS disruption, BBB tight-junction opening, increased permeability Blood-Brain Barrier Breakdown Plasma transudate into interstitium VASOGENIC EDEMA (parieto-occipital) Posterior > anterior (sparse sympathetic innervation)

Figure 1. PRES pathophysiology – converging pathways producing posterior-predominant vasogenic edema.

S2. Clinical Presentation & Imaging Diagnosis

Symptom Spectrum

PRES presents subacutely over hours to days. The four cardinal manifestations are encephalopathy, seizures, headache, and visual disturbances – though no single symptom is universal.

SymptomFrequencyCharacteristics
Encephalopathy50-80%Confusion, somnolence, agitation; rarely coma
Seizures60-75%Generalized tonic-clonic most common; focal-onset 20%; status epilepticus 5-15%
Headache50%Diffuse, dull or throbbing; rarely thunderclap (raises RCVS overlap)
Visual disturbances40%Cortical blindness, hemianopsia, visual hallucinations, blurry vision
Focal deficits10-15%Hemiparesis, aphasia (suggests atypical or hemorrhagic PRES)
Acute hypertension70-80%Often abrupt rise from baseline rather than absolute value

MRI Findings – The Diagnostic Standard

MRI brain is the diagnostic gold standard. Order: T2/FLAIR (vasogenic edema), DWI/ADC (exclude infarction), GRE/SWI (detect hemorrhage), MRA (exclude RCVS, dissection).

SequencePRES FindingStroke Comparison
T2/FLAIRBilateral, often symmetric hyperintensity in parieto-occipital cortex/subcortical white matterUnilateral, vascular territory
DWINo restriction (high ADC = vasogenic edema)Restriction (low ADC = cytotoxic edema)
GRE/SWIMicrobleeds 15%; intraparenchymal hemorrhage 5-15%; SAH 5%Hemorrhage in 15-20% of strokes
Post-contrast T1Patchy enhancement in 20-40% (BBB breakdown)Variable; depends on stage
MRAUsually normal; vasoconstriction overlap with RCVSVessel occlusion

Imaging Patterns – Classic vs Atypical

  • Classic parieto-occipital (50-60%): Bilateral, symmetric, posterior dominant
  • Holohemispheric watershed (20-25%): Linear edema along ACA-MCA-PCA borders
  • Superior frontal sulcus pattern (15-20%): Bilateral medial frontal involvement
  • Brainstem/cerebellar variant (10-15%): Pontine and cerebellar hemispheric edema, can mimic infarct
  • Asymmetric or unilateral (uncommon): Higher diagnostic difficulty; biopsy occasionally needed to exclude tumor

Differential Diagnosis

Critical Mimics to Exclude

  • Acute ischemic stroke (PCA territory): DWI restriction; unilateral; vascular distribution
  • Cerebral venous sinus thrombosis: MRV shows filling defect; hemorrhagic infarct possible
  • Reversible cerebral vasoconstriction syndrome (RCVS): Thunderclap headache; angiographic beading; 8-38% overlap with PRES
  • Autoimmune/limbic encephalitis: Medial temporal lobe involvement; CSF pleocytosis; antibodies (anti-NMDAR, anti-LGI1)
  • Progressive multifocal leukoencephalopathy (PML): Subacute progression in immunocompromised; JC virus PCR
  • Hypertensive intracerebral hemorrhage: CT/GRE shows acute blood; basal ganglia/thalamic typical
  • Acute toxic leukoencephalopathy: Specific drug exposure; symmetric white matter; DWI may restrict

Lumbar Puncture & EEG

LP is not diagnostic but useful to exclude infection or autoimmune encephalitis. CSF in PRES typically shows mildly elevated protein with normal cell count. EEG demonstrates posterior slowing or epileptiform discharges; continuous EEG is mandatory in nonconvulsive status epilepticus suspicion.

PRES — Comparison Comparison table: PRES — Comparison Hypertensive crisis Eclampsia/preeclampsia Immunosuppressants Renal disease Autoimmune Description Most common; SBP often >180; relative rise more important than absolute Pregnancy-associated; mg sulfate + delivery Cyclosporine, tacrolimus most common; chemotherapy (bevacizumab, cisplatin) AKI, transplant, hemodialysis; volume overload contribution SLE, vasculitis, TTP; IVIG occasionally trigger
PRES — Comparison

S3. Acute Management Algorithm

Three priorities operate in parallel: (1) controlled BP reduction, (2) seizure control, (3) trigger removal. ICU admission is the default for hypertensive PRES, status epilepticus, depressed consciousness, or hemorrhagic transformation.

Step 1 – Blood Pressure Control

The goal is gradual reduction of MAP by 20-25% within the first hour, reaching MAP 105-125 mmHg. Avoid abrupt drops (especially below MAP 95 mmHg) to prevent watershed infarction in already vulnerable territories.

DrugDoseNotes
Nicardipine (preferred)5 mg/hr IV start, titrate by 2.5 mg/hr q5-15 min, max 15 mg/hrSmooth titration; minimal reflex tachycardia; no hepatic metabolism issue
Labetalol20 mg IV bolus, then double q10 min (40, 80, 80, 80, max 300 mg); or 0.5-2 mg/min infusionCombined alpha+beta blockade; first choice in pregnancy/eclampsia (with magnesium)
Clevidipine1-2 mg/hr IV, double q90 sec to target, max 21 mg/hrUltra-short half-life (1 min); ideal for rapid titration; soybean/egg allergy contraindication
Esmolol500 mcg/kg IV bolus, then 50-200 mcg/kg/min infusionAdjunct for tachycardia; not monotherapy
Hydralazine10-20 mg IV q4-6h PRNLess predictable; pregnancy alternative; may cause reflex tachycardia
Nitroprusside0.3 mcg/kg/min IV, max 10 mcg/kg/minAvoid >48h (cyanide toxicity); raises ICP – last-line in PRES

Avoid in PRES

  • Sublingual or oral nifedipine (uncontrolled drop)
  • IV bolus enalaprilat (variable response)
  • Diuretics as first-line (most PRES patients are euvolemic; volume depletion worsens cerebral hypoperfusion after BP reduction)

Step 2 – Seizure Management

Seizures occur in 60-75% of PRES. Treat all observed seizures and consider AED loading even after a single generalized tonic-clonic episode.

  • First-line: Levetiracetam 500-1500 mg PO/IV BID, load with 60 mg/kg IV (max 4500 mg) for active seizures
  • Alternative: Fosphenytoin 20 mg PE/kg IV load at 150 mg PE/min, then 4-6 mg PE/kg/day divided BID-TID
  • Status epilepticus: Lorazepam 0.1 mg/kg IV (max 4 mg/dose), then load levetiracetam or fosphenytoin; refractory status requires midazolam/propofol drip + continuous EEG
  • Eclampsia-related PRES: Magnesium sulfate 4-6 g IV loading over 15-20 min, then 1-2 g/hr infusion for 24h after delivery; superior to AEDs in this population
  • Duration: Continue AED 3-6 months after recovery; taper if no recurrent seizures and MRI normalized

Step 3 – Trigger Removal

TriggerAction
Tacrolimus / CyclosporineHold immediately; switch to alternative (e.g., tacrolimus to sirolimus, or temporary mycophenolate monotherapy with steroid bridge); consult transplant team within 6h
Bevacizumab / VEGF inhibitorHold; defer next cycle; rechallenge generally avoided after PRES
Cytotoxic chemotherapy (cisplatin, gemcitabine)Hold offending agent; review regimen with oncology
Pregnancy/eclampsiaExpedite delivery (definitive treatment); magnesium sulfate; BP control
PheochromocytomaPhenoxybenzamine alpha-block before any beta-block; surgical resection after stabilization
Renal failure / TTP / HUSTreat underlying cause; plasmapheresis if TTP; dialysis as needed
CAR-T cell therapy ICANSTocilizumab 8 mg/kg IV (max 800 mg); dexamethasone 10 mg IV q6h; ICU monitoring

Step 4 – Supportive ICU Care

  • Continuous BP monitoring (arterial line preferred)
  • Continuous cardiac and SpO2 monitoring
  • Continuous EEG if depressed consciousness or status epilepticus suspected
  • Strict fluid balance; avoid hypervolemia (worsens edema) and hypovolemia (worsens cerebral hypoperfusion)
  • DVT prophylaxis with intermittent pneumatic compression initially; pharmacologic prophylaxis only after hemorrhage excluded
  • Glycemic control 140-180 mg/dL
  • Repeat MRI at 1-3 months to confirm radiographic resolution

When to Refer / Escalate

  • Neurology/Neurocritical Care: All confirmed PRES cases warrant neurology consultation; ICU transfer for status epilepticus, GCS less than 12, hemorrhage, or refractory hypertension
  • Transplant Medicine: Within 6h for any solid organ or stem cell transplant patient on calcineurin inhibitors
  • Obstetrics/MFM: Eclampsia with PRES requires delivery planning regardless of gestational age beyond viability
  • Neurosurgery: Significant intraparenchymal hemorrhage with mass effect
PRES — Procedure Steps Surgical stepper: PRES — Procedure Steps PRES — Procedure Steps 1 Diagnosis MRI brain: bilateral parieto-occipital vasogenic edema (T2/FLAIR hyperintense, no DWI 2 Identify + remove trigger Stop offending immunosuppressant if causative; deliver fetus in eclampsia; treat sepsis if 3 BP control Reduce MAP by 20-25% over hours (NOT rapid); IV labetalol, nicardipine, hydralazine; avoid sodium ni 4 Seizure management Levetiracetam 1-2g IV load → 1g BID maintenance; lorazepam for active seizures 5 Eclampsia management Magnesium sulfate 4-6g IV load + 1-2 g/h infusion + delivery (may need C-section) 6 Recovery monitoring Repeat MRI at 1-3 weeks (resolution expected); ICU level care during acute phase; gradual return to
PRES — Procedure Steps

S4. Special Populations & Atypical Variants

Pregnancy and Eclamptic PRES

Up to 90% of eclampsia cases show PRES on MRI. Magnesium sulfate is first-line for both BP-related neuroprotection and seizure prophylaxis. Definitive treatment is delivery, ideally within 24h. Postpartum PRES can occur up to 6 weeks after delivery, classically presenting as new-onset headache and visual disturbances; treat as standard PRES with BP control plus magnesium re-loading. Recurrence risk in subsequent pregnancies is 5-15%; aspirin 81 mg PO daily from 12 weeks reduces preeclampsia risk in high-risk women.

Transplant PRES

Calcineurin inhibitor PRES occurs in 0.4-6% of solid organ transplant and 7-9% of allogeneic HSCT recipients. The majority occur within the first 3 months post-transplant. Tacrolimus levels are often within therapeutic range (5-15 ng/mL), so do not exclude PRES based on drug levels. After PRES resolution, restarting calcineurin inhibitor at 50% dose with close BP and neurologic monitoring is feasible if no alternative immunosuppression exists; recurrence rate 5-10%.

Hemorrhagic PRES

Approximately 15% of PRES has associated hemorrhage: microbleeds (60% of hemorrhagic PRES), focal intraparenchymal hematoma (25%), subarachnoid hemorrhage (15%). Risk factors include thrombocytopenia (platelets less than 100,000), anticoagulation, allogeneic HSCT, and severe coagulopathy. Mortality in hemorrhagic PRES reaches 25-40% versus 3-5% in non-hemorrhagic PRES. Reverse anticoagulation; transfuse platelets to maintain greater than 100,000; avoid antiplatelets/anticoagulants; neurosurgical consultation for symptomatic hematoma greater than 30 mL.

Pediatric PRES

Most often associated with chemotherapy (acute lymphoblastic leukemia receiving methotrexate, cytarabine), HSCT, and renal disease. Presentation often begins with seizures rather than encephalopathy. Hypertension thresholds use age-/sex-/height-adjusted percentiles. Levetiracetam dosing 20-40 mg/kg/day divided BID; nicardipine 0.5-1 mcg/kg/min titrated.

Autoimmune PRES

SLE (especially with active nephritis), scleroderma renal crisis, GPA, and TTP/HUS account for 10-15% of PRES. Treat underlying disease aggressively (high-dose steroids for SLE flare; ACEi for scleroderma renal crisis; plasmapheresis for TTP; complement inhibitor for atypical HUS). Steroids do NOT treat PRES itself – the mechanism is mechanical (BBB breakdown), not inflammatory.

Atypical Anatomic Variants

VariantImaging PatternClinical Clue
Brainstem/cerebellar PRESPontine and cerebellar hemispheric T2 hyperintensityVertigo, ataxia, cranial nerve deficits; can mimic basilar stroke
Asymmetric/unilateral PRESOne hemisphere affected; rare overlap with low-grade glioma imagingOften with prior unilateral cerebrovascular pathology; may need biopsy if not regressing
Spinal cord PRES (PRES-SCI)Centrally located T2 hyperintensity in cervical/upper thoracic cordSevere hypertension; rare; often postpartum
Holohemispheric watershedLinear edema along ACA-MCA-PCA junctionHemodynamic compromise; severe hypotension or hyperperfusion

S5. Monitoring, Referral & Follow-up

Inpatient Monitoring

  • Continuous BP monitoring with arterial line during active titration
  • Continuous EEG for any patient with depressed consciousness, status epilepticus history, or refractory seizures
  • Daily neurologic exam (NIHSS, GCS)
  • Repeat MRI at 48-72h if neurologic deterioration or atypical presentation
  • Daily basic metabolic panel, magnesium, phosphate, ionized calcium
  • Coagulation studies if hemorrhage detected or anticoagulant exposure
  • Drug level monitoring if on calcineurin inhibitor (tacrolimus 5-10 ng/mL trough; cyclosporine 100-250 ng/mL trough)

Discharge Criteria

  • BP stable at MAP less than 120 mmHg on oral antihypertensives for 24h
  • Seizure-free for 24-48h on stable AED dose
  • Improved or resolved encephalopathy (GCS 14-15)
  • Trigger addressed and follow-up plan in place
  • Outpatient neurology and primary subspecialty follow-up scheduled within 1-2 weeks

Outpatient Follow-up

Time PointAction
2 weeks post-dischargeNeurology clinic visit; BP review; AED levels if applicable; medication review
1 monthRepeat MRI brain; ambulatory BP monitoring; ophthalmology if visual symptoms persisted
3 monthsRepeat MRI to confirm resolution; consider AED taper if normalized imaging and no recurrent seizures
6 monthsFinal neurology assessment; long-term AED decision; counseling on driving restrictions per local law
AnnuallyBP surveillance; if persistent radiographic abnormalities, continued imaging surveillance

Long-Term Sequelae Monitoring

  • Cognitive impairment: 10-25% experience persistent attention/memory deficits; refer for neuropsychologic assessment if symptomatic at 6 months
  • Visual deficits: Cortical visual loss may persist in 5-10%; ophthalmology + low vision rehab
  • Recurrent seizures: Less than 5% develop chronic epilepsy; long-term AED rarely needed
  • Recurrence of PRES: 5-10% overall; higher in transplant patients with continued calcineurin inhibitor exposure
  • Driving restrictions: Most jurisdictions require 6-12 months seizure-free

S7. Practice Insights: Bedside Priorities in PRES

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Vision that goes strange hours after a tacrolimus dose or a hypertensive crisis is the presentation nobody expects to be a scan diagnosis, and the disease’s “reversible” label is only honored when BP is controlled carefully and the offending drug is removed fast. In experienced hands the pivot points are NOT overcorrecting BP (avoid watershed ischemia from rapid drop), recognizing atypical MRI patterns (PRES isn’t always posterior), and treating eclampsia-PRES with magnesium + delivery rather than just antihypertensives. Three items warrant tracking during acute management: BP trajectory (gradual reduction, not crash), MAP target, and neurologic exam every hour during BP correction.

What the Guideline Misses — Don’t Crash the BP

The temptation in PRES + severe hypertension is to drop BP rapidly. In experienced practice MAP reduction should be no more than 20-25% in the first hour to prevent watershed ischemia. Target SBP 140-160 over 6-12 hours, not 30 minutes. Nicardipine or labetalol drips with bedside titration. Nitroprusside is fine short-term but clinicians avoid in renal patients (cyanide). Crashed BP can convert reversible vasogenic edema to permanent cytotoxic injury.

Patterns That Recur — Atypical PRES Distribution

About 20-30% of PRES cases have atypical MRI: brainstem, basal ganglia, frontal cortex, deep white matter. In routine practice PRES is NOT excluded because imaging isn’t “posterior enough.” MRI with FLAIR + DWI + gradient echo (look for microhemorrhages, which suggest worse outcome) — the clinical picture + drug/HTN context drives diagnosis. Non-classic imaging is frequent enough that lesion distribution alone cannot rule PRES out.

Tacrolimus / Calcineurin Substitution

Tacrolimus and cyclosporine both cause PRES; substituting one for the other risks recurrence. In routine practice the calcineurin inhibitor is HELD entirely, with substitution to an mTOR inhibitor (sirolimus, everolimus) or a move to a mycophenolate-based regimen depending on transplant team preference. Because recurrence follows substitution within the same class, the safer move is switching CLASS rather than swapping agent.

Bedside Heuristic — Eclampsia PRES = Magnesium + Delivery

Eclampsia-related PRES is a different beast. Magnesium sulfate 4-6 g IV load + 1-2 g/hr maintenance is the antiseizure intervention; delivery of the fetus is definitive treatment. Antihypertensives (labetalol, hydralazine, nicardipine) are bridge therapy. Delaying delivery to “stabilize BP” is the wrong move; deliver as soon as feasible regardless of BP control level.

A Case That Reframes the Approach — Watershed Ischemia From Aggressive BP Drop

A man in his early 50s post kidney transplant on tacrolimus presented with seizure and altered mental status. BP 220/120, MRI showed classic posterior parieto-occipital vasogenic edema — PRES. Outside ICU team aggressively dropped BP with nitroprusside infusion: SBP went from 220 to 110 within 60 minutes (50% reduction). New right-sided weakness developed; repeat MRI showed bilateral watershed cortical infarcts. He recovered partially but left with mild residual deficit at 6 months. What clinicians learned: PRES + hypertension demands gradual BP correction. The brain’s autoregulation is impaired; rapid BP drop converts reversible edema to cytotoxic infarction. Best practice is a written BP target curve on every PRES chart: “SBP 200→180 over 1h, 180→160 over next 2h, then maintenance 140-160.”

Bedside lesson: PRES + severe HTN = gradual BP reduction (20-25% MAP/hr max). Crashed BP causes watershed ischemia. Written BP target curve prevents overcorrection.

Protocol Refinements That Diverge From Standard Guidelines

  1. Written BP target curve on every PRES chart. Specify SBP at +1h, +6h, +12h. Prevents accidental overcorrection by overnight teams. MAP reduction ≤20-25% per hour, target SBP 140-160 by 12-24 hours.
  2. MRI FLAIR + DWI + GRE — not just routine MRI. FLAIR shows vasogenic edema (classic), DWI rules out cytotoxic conversion to infarct, GRE shows microhemorrhages (predicts worse outcome). A minority of PRES cases show cytotoxic conversion on DWI, requiring more aggressive intervention.
  3. Switch CLASS, not just agent, when culprit drug is tacrolimus or cyclosporine. mTOR inhibitors (sirolimus, everolimus) or MMF-based regimen. Substituting cyclosporine for tacrolimus has 20% recurrence risk in clinical experience.
  4. Eclampsia-PRES: magnesium + delivery, don’t delay for BP. Magnesium sulfate 4-6 g IV load → 1-2 g/hr × 24h post-delivery. Continuous fetal monitoring. Antihypertensives bridge only; delivery is the cure.
PRES Algorithm — Gradual BP Control, Atypical Pattern Recognition, Drug Class Switch PRES recognition → gradual BP correction → MRI pattern + DWI → withdraw culprit drug → eclampsia pathway separate PRES Algorithm — Gradual BP, Drug Class Switch, Eclampsia ≠ Just BP Seizure / AMS / visual loss + HTN/drug/eclampsia MRI FLAIR + DWI + GRE — bilateral edema ⚠️ GRADUAL BP CONTROL — MAP REDUCTION ≤20-25% PER HOUR Nicardipine/labetalol drip; target SBP 140-160 over 6-12 hours; written curve prevents overcorrection Identify etiology HTN crisis / drug / eclampsia / renal / autoimmune HTN crisis Nicardipine/labetalol drip Avoid nitroprusside in CKD Long-term BP control plan Drug-induced (tacro/CSA/chemo) HOLD culprit drug Switch CLASS not agent (mTOR inhibitor or MMF) Eclampsia-PRES MgSO4 4-6g load + 1-2g/h DELIVERY is the cure Don’t delay for BP Atypical pattern: brainstem/basal ganglia/frontal — don’t exclude PRES on non-classic MRI DWI rules out cytotoxic conversion; GRE microhemorrhages predict worse outcome Practice insight: aggressive BP drop converts reversible to permanent. Written target curve. — gomdori, MD

S6. Pitfalls, FAQ & Pearls

Pearl: BP Trajectory Matters More Than Absolute Value

A patient with chronic hypertension and baseline BP 180/100 may develop PRES at 220/120, while a normotensive pregnant woman can develop eclamptic PRES at 160/100. Focus on the magnitude and rapidity of BP rise from the patient’s baseline, not the absolute number. Aggressive normalization in chronically hypertensive patients risks watershed infarction.

Pitfall: Mistaking PRES for Stroke and Giving Thrombolysis

Atypical PRES can present with focal deficits and unilateral edema. If DWI shows no restriction but the team rushes to tPA based on the time window, hemorrhagic conversion is catastrophic. Always confirm DWI/ADC before thrombolysis – vasogenic edema (PRES) does not restrict; cytotoxic edema (stroke) does.

Pearl: Tacrolimus Level Within Range Does Not Exclude PRES

Calcineurin inhibitor PRES is mechanistic, not dose-related. Endothelial dysfunction occurs at therapeutic and subtherapeutic levels alike. Hold the drug immediately on suspicion; do not wait for level results to drive the decision.

Pitfall: Continuing Bevacizumab After PRES

Rechallenge with the offending VEGF inhibitor after PRES carries 30-50% recurrence risk. Once a patient develops PRES on bevacizumab, sunitinib, or sorafenib, the agent is generally contraindicated. Discuss alternative regimens with oncology before any rechallenge.

Pearl: Magnesium Sulfate Is First-Line in Eclamptic PRES

For pregnancy-related PRES with eclampsia, magnesium sulfate (4-6 g loading, then 1-2 g/hr) outperforms phenytoin and benzodiazepines in seizure prevention and maternal mortality. Do not substitute with conventional AEDs; use magnesium plus labetalol or hydralazine for BP, and expedite delivery.

Pitfall: Aggressive Diuresis Worsens PRES

Loop diuretics deplete intravascular volume, paradoxically worsening cerebral hypoperfusion in PRES territories vulnerable to watershed injury after BP reduction. Reserve diuretics for true volume overload (heart failure, pulmonary edema). Maintain euvolemia with isotonic fluids during BP titration.

Frequently Asked Questions

Q. What blood pressure target should be achieved in PRES?
Reduce mean arterial pressure (MAP) by 20-25% within the first hour, targeting MAP 105-125 mmHg, using IV nicardipine 5 mg/hr titrated by 2.5 mg/hr q5-15 min, labetalol 20 mg IV bolus then double q10 min (max 300 mg), or clevidipine 1-2 mg/hr titrated. Avoid abrupt reductions below MAP 95 mmHg, which can cause watershed infarction. For eclampsia-related PRES, magnesium sulfate 4-6 g IV loading followed by 1-2 g/hr is first-line.
Q. How is PRES diagnosed on MRI?
MRI demonstrates bilateral, often symmetric vasogenic edema, classically in the parieto-occipital lobes (95% of cases) on T2/FLAIR sequences. Diffusion-weighted imaging (DWI) shows no restriction (high ADC values), distinguishing PRES from acute ischemic stroke. Atypical patterns include frontal lobe (40%), brainstem (10-15%), cerebellar (35%), basal ganglia, and deep white matter involvement. Approximately 15% have associated hemorrhage (microbleeds, intraparenchymal, or subarachnoid).
Q. Which immunosuppressants most commonly trigger PRES?
Calcineurin inhibitors (tacrolimus and cyclosporine) are the most common triggers, occurring in 0.4-6% of solid organ transplant recipients and up to 7-9% of allogeneic stem cell transplants. PRES can occur at therapeutic drug levels and is not strictly dose-dependent. Other triggers include cytotoxic chemotherapy (cisplatin, gemcitabine, cytarabine), bevacizumab and other anti-VEGF agents, sunitinib, sorafenib, and CAR-T cell therapy. Withdrawal or substitution of the offending agent is essential to recovery.
Q. Should antiepileptic drugs be continued long-term after PRES?
For most patients, AEDs (typically levetiracetam 500-1500 mg PO BID or fosphenytoin 20 mg/kg IV loading) are continued for 3-6 months after seizure control and clinical recovery, then tapered if neuroimaging has normalized and no recurrent seizures occur. Long-term AED therapy is not routinely required because the risk of recurrent seizures after PRES resolution is low (less than 5%). Status epilepticus during PRES warrants more aggressive ICU-level management with continuous EEG monitoring.
Q. What distinguishes PRES from reversible cerebral vasoconstriction syndrome (RCVS)?
RCVS presents with thunderclap headaches and segmental cerebral artery vasoconstriction on angiography, while PRES presents with subacute encephalopathy and vasogenic edema on MRI. The two conditions overlap in 8-38% of cases, sharing triggers (postpartum, sympathomimetics, immunosuppressants). RCVS shows beaded vessel narrowing reversing within 12 weeks; PRES shows posterior-predominant T2/FLAIR hyperintensities reversing within 1-3 months. Both require BP control and trigger removal.
Q. What is the prognosis for PRES?
Approximately 75-90% of patients achieve complete clinical and radiographic recovery within 1-3 months when triggers are promptly addressed. However, mortality reaches 3-15%, particularly with associated hemorrhage, status epilepticus, or delayed diagnosis. Permanent neurologic deficits (visual field defects, focal weakness, cognitive impairment) occur in 10-25%. Cytotoxic edema or infarction on initial MRI predicts worse outcome. Recurrence is uncommon (less than 5%) when underlying causes are controlled.

Leave a Reply

Your email address will not be published. Required fields are marked *